Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epitope cuts staff in bid for profitability

This article was originally published in Clinica

Executive Summary

Diagnostics manufacturer Epitope is cutting its workforce by 28% as part of a restructuring programme. This will lead to a $500,000 charge in the third quarter, the company warns, but will result in cost savings of more than $2 million a year. The move is part of Epitope's plan to focus its business and bring the company to profitability, says CEO Adolph Ferro. "We will now have an organisation that has a lower-cost profile, yet is fully resourced to meet the needs of our customers and match the plans of our medical diagnostics marketing partner, SmithKline Beecham."

You may also be interested in...



Impella Safety Update: Data Supports Pump For Qualified Patients

Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.

Quality, Safety, MDSAP A Focus For Medtech In New USMCA Trade Agreement

The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.

Novo Nordisk Targets Smart Insulin, Stem Cell-Therapies

Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.

Topics

UsernamePublicRestriction

Register

MT093591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel